Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis

Context: In December 2020, the US Food and Drug Administration approved a 68Ga-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-11) for positron emission tomography (PET) in patients with suspected prostate cancer (PCa) metastasis who are candidates for initial definitive therapy. 68Ga-P...

Full description

Bibliographic Details
Main Authors: Sui Wai Ling, Anouk C. de Jong, Ivo G. Schoots, Kazem Nasserinejad, Martijn B. Busstra, Astrid A.M. van der Veldt, Tessa Brabander
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:European Urology Open Science
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168321006856